News | May 11, 2010

PET Improves Prognosis in Locally Advanced Breast Cancer

 pet image of breast cancer

May 11, 2010 - An aggressive weekly preoperative regimen of positron emission tomography (PET) significantly improved distant metastasis-free and overall survival in patients with highly aggressive breast tumors.

Patients in the randomized Italian SICOG 9908 trial had locally advanced breast cancer. The disease break down as follows: 136 patients had T4a-c disease, 47 had inflammatory breast cancer and 17 had N2 breast cancer.

Patients underwent 12 weekly cycles of PET (cisplatin, epirubicin, paclitaxel), compared with four tri-weekly cycles of epirubicin and paclitaxel (ET), given preoperatively to women with locally advanced breast cancer.

The researchers found distant metastasis-free survival (DMFS) at five years was significantly better in the PET patients (73 vs. 55 percent; P = .037). PET also significantly improved elapse-free survival (RFS) rates in patients with grade 3 tumors.

The 12-week therapy improved both DMFS and overall survival (OS) in patients with locally advanced breast cancer, over the survival outcomes attained with four triweekly cycles of ET.

The study showed that patients receiving PET had a significantly lower risk of distant metastasis and death.

The authors stated: “These data confirm that patients with inflammatory disease should not have breast-conserving therapy. Further, stage three B patients should have an accurate initial work-up, including (Fludeoxyglucose) FDG-PET and dynamic magnetic resonance imaging, to rule out occult and distant metastases.”

They also noted, “irradiation of both internal mammary and supraclavicular nodal regions should be mandatory in patients with stage three B disease at diagnosis, regardless of their pathologic response to neoadjuvant chemotherapy.”

Reference: Frasci, G., D'Aiuto, G., et al. “Preoperative Weekly Cisplatin, Epirubicin, and Paclitaxel (PET) Improves Prognosis in Locally Advanced Breast Cancer Patients: An Update of the Southern Italy Cooperative Oncology Group (SICOG) Randomised Trial 9908.” Ann Oncol. 2010 Apr 1;21(4):707-716. Southern Italy Cooperative Oncology Group, Italy.

For more information: annonc.oxfordjournals.org/content/by/year

Related Content

Subtle Medical Receives FDA Clearance, CE Mark for SubtlePET
Technology | PET Imaging | December 05, 2018
Subtle Medical announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market SubtlePET. Subtle...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
Feature | PET Imaging | November 07, 2018 | By Greg Freiherr
Positron emission tomography (PET) is getting ready to venture outside oncology, cardiology and mainstream neurology....
Podcast | PET Imaging | November 07, 2018
PET is getting ready to venture outside oncology, cardiology and mainstream neurology.
PET Imaging Offers New Possibilities in Chronic Liver Disease Management

Hepatic 18F-FDG, 18F-FAC, and 18F-DFA accumulation are affected in a mouse model of autoimmune hepatitis. (A) Histochemical and immunohistochemical analyses of liver sections from vehicle- and ConA-treated mice. Scale bars represent 50 microns. Transverse PET/CT images (B) and quantification (C) of vehicle- and ConA-treated mice injected with 18F-FDG, 18F-FAC, and 18FDFA. Livers are outlined in a white dotted line. Quantification represents radiotracer accumulation in the liver normalized to a background organ. Image courtesy of Salas J.R., Chen B.Y., Wong A., et al.

News | PET Imaging | October 24, 2018
While liver biopsies are powerful and reliable, they are also invasive, painful, limited and subject to complications....
Huntsman Cancer Institute Installs First Preclinical nanoScan 3T PET/MRI in U.S.
News | PET-MRI | October 10, 2018
The Center for Quantitative Cancer Imaging at Huntsman Cancer Institute (HCI) at the University of Utah in Salt Lake...
Technology and Radionucleotide Development Will Fuel Mobile Gamma Camera Adoption
News | Nuclear Imaging | September 27, 2018
Advancements in healthcare technology, particularly in the surgery category, have led to an increasing adoption of...